deferoxamine has been researched along with Day Blindness in 25 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To report a case of acute bilateral central serous retinopathy associated with deferoxamine therapy in the context of paroxysmal nocturnal hemoglobinuria." | 7.83 | Bilateral central serous retinopathy in a patient with paroxysmal nocturnal hemoglobinuria treated with deferoxamine. ( Giasin, O; Kaneshyogan, H; Makrygiannis, G; Sian, IS; Vahdani, K, 2016) |
| "To report a case of acute bilateral central serous retinopathy associated with deferoxamine therapy in the context of paroxysmal nocturnal hemoglobinuria." | 3.83 | Bilateral central serous retinopathy in a patient with paroxysmal nocturnal hemoglobinuria treated with deferoxamine. ( Giasin, O; Kaneshyogan, H; Makrygiannis, G; Sian, IS; Vahdani, K, 2016) |
| "Deferoxamine (DFO) is a chelating agent used widely for the treatment of transfusional hemochromatosis." | 3.74 | Deferoxamine-related ocular toxicity: incidence and outcome in a pediatric population. ( Baath, JS; Chun, A; Kirby, M; Lam, WC, 2008) |
| "Of 89 patients receiving nightly subcutaneous deferoxamine for transfusion-dependent thalassemia major or Diamond-Blackfan anemia, 13 presented with visual loss or deafness of acute onset or both." | 3.67 | Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions. ( Buncic, JR; Chew, E; Gallant, T; Harrison, RV; Keenan, N; Logan, W; Mitchell, D; Olivieri, NF; Ricci, G; Skarf, B, 1986) |
| "Deferoxamine is a chelating agent that has extended the life expectancy of patients with thalassemia." | 1.33 | Auditory and visual toxicity during deferoxamine therapy in transfusion-dependent patients. ( Chen, LJ; Chen, SH; Cheng, SY; Liang, DC; Lin, HC; Liu, HC, 2005) |
| "We report how acute visual disorders occurred after performing a desferrioxamine (DFO) test in patients on regular dialysis treatment suspected of having aluminium overload." | 1.28 | Acute visual disorders in patients on regular dialysis given desferrioxamine as a test. ( Apostoli, P; De Maria, G; Feller, P; Maiorca, R; Mombelloni, S; Movilli, E; Ravelli, M; Scaroni, P; Sciuto, G; Valotti, C, 1990) |
| " Periodical audiovisual monitoring should be performed on hemodialyzed patients receiving the drug in order to detect adverse effects as early as possible." | 1.28 | Ocular and auditory toxicity in hemodialyzed patients receiving desferrioxamine. ( Cases, A; Griño, MC; Kelly, J; Lopez-Pedret, J; Revert, L; Sabater, F; Torras, A, 1990) |
| "To determine the frequency of eye and auditory complications and their relationship to drug dosage and iron stores in patients receiving deferoxamine, we studied 52 regularly transfused patients who received deferoxamine by subcutaneous or intravenous infusion in doses from 26 to 136 mg/kg/day, and whose serum ferritin levels of 185 to 17,775 micrograms/L reflected a wide range of iron stores." | 1.28 | Vision and hearing during deferoxamine therapy. ( Cohen, A; Konkle, DF; Martin, M; Mizanin, J; Schwartz, E, 1990) |
| "When deferoxamine therapy was discontinued and serial studies were performed, audiograms in seven cases reverted to normal or near normal within two to three weeks, and nine of 13 patients with symptoms became asymptomatic." | 1.27 | Serial studies of auditory neurotoxicity in patients receiving deferoxamine therapy. ( Boyden, MH; Carley, H; Freedman, MH; Gallant, LA; Gallant, T, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 12 (48.00) | 18.7374 |
| 1990's | 7 (28.00) | 18.2507 |
| 2000's | 4 (16.00) | 29.6817 |
| 2010's | 2 (8.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gelman, R | 1 |
| Kiss, S | 1 |
| Tsang, SH | 1 |
| Vahdani, K | 1 |
| Makrygiannis, G | 1 |
| Kaneshyogan, H | 1 |
| Sian, IS | 1 |
| Giasin, O | 1 |
| Baath, JS | 1 |
| Lam, WC | 1 |
| Kirby, M | 1 |
| Chun, A | 1 |
| Arora, A | 1 |
| Wren, S | 1 |
| Gregory Evans, K | 1 |
| Chen, SH | 1 |
| Liang, DC | 1 |
| Lin, HC | 1 |
| Cheng, SY | 1 |
| Chen, LJ | 1 |
| Liu, HC | 1 |
| Simon, P | 1 |
| Ang, KS | 1 |
| Meyrier, A | 1 |
| Allain, P | 1 |
| Mauras, Y | 1 |
| Borgna-Pignatti, C | 1 |
| De Stefano, P | 1 |
| Broglia, AM | 1 |
| Dennerlein, JA | 1 |
| Lang, GE | 1 |
| Stahnke, K | 1 |
| Kleihauer, E | 1 |
| Lang, GK | 1 |
| Giardina, PJ | 1 |
| Grady, RW | 1 |
| Bhattacharya, M | 1 |
| Ponka, P | 1 |
| Hardy, P | 1 |
| Hanna, N | 1 |
| Varma, DR | 1 |
| Lachapelle, P | 1 |
| Chemtob, S | 1 |
| Gartaganis, SP | 1 |
| Zoumbos, N | 1 |
| Koliopoulos, JX | 1 |
| Mela, EK | 1 |
| Triantafyllou, N | 1 |
| Fisfis, M | 1 |
| Sideris, G | 1 |
| Triantafyllou, D | 1 |
| Rombos, A | 1 |
| Vrettou, H | 1 |
| Mantouvalos, V | 1 |
| Politi, C | 1 |
| Malliara, S | 1 |
| Papageorgiou, C | 1 |
| Ravelli, M | 1 |
| Scaroni, P | 1 |
| Mombelloni, S | 1 |
| Movilli, E | 1 |
| Feller, P | 1 |
| Apostoli, P | 1 |
| De Maria, G | 1 |
| Valotti, C | 1 |
| Sciuto, G | 1 |
| Maiorca, R | 1 |
| Cases, A | 2 |
| Kelly, J | 2 |
| Sabater, F | 1 |
| Torras, A | 2 |
| Griño, MC | 1 |
| Lopez-Pedret, J | 1 |
| Revert, L | 2 |
| Cohen, A | 1 |
| Martin, M | 1 |
| Mizanin, J | 1 |
| Konkle, DF | 1 |
| Schwartz, E | 1 |
| Freedman, MH | 2 |
| Bentur, Y | 1 |
| Koren, G | 1 |
| Pall, H | 1 |
| Blake, DR | 1 |
| Winyard, P | 1 |
| Lunec, J | 1 |
| Williams, A | 1 |
| Good, PA | 1 |
| Kritzinger, EE | 1 |
| Cornish, A | 1 |
| Hider, RC | 1 |
| Rubinstein, M | 1 |
| Dupont, P | 1 |
| Doppee, JP | 1 |
| Dehon, C | 1 |
| Ducobu, J | 1 |
| Hainaut, J | 1 |
| Sabater, J | 1 |
| Campistol, JM | 1 |
| Montoliu, J | 1 |
| López, I | 1 |
| Olivieri, NF | 1 |
| Buncic, JR | 1 |
| Chew, E | 1 |
| Gallant, T | 2 |
| Harrison, RV | 1 |
| Keenan, N | 1 |
| Logan, W | 1 |
| Mitchell, D | 1 |
| Ricci, G | 1 |
| Skarf, B | 1 |
| Boyden, MH | 1 |
| Gallant, LA | 1 |
| Carley, H | 1 |
| Bournerias, F | 1 |
| Monnier, N | 1 |
| Dufier, JL | 1 |
| Réveillaud, RJ | 1 |
| Pengloan, J | 1 |
| Dantal, J | 1 |
| Rossazza, C | 1 |
| Abazza, M | 1 |
| Nivet, H | 1 |
| Orton, RB | 1 |
| de Veber, LL | 1 |
| Sulh, HM | 1 |
| van Oye, R | 1 |
2 reviews available for deferoxamine and Day Blindness
| Article | Year |
|---|---|
Chelation therapy in beta-thalassemia: the benefits and limitations of desferrioxamine.
Topics: Adolescent; Adult; Chelating Agents; Chelation Therapy; Child; Deferoxamine; Growth Disorders; Heari | 1995 |
Biological and toxic properties of deferoxamine.
Topics: Cataract; Cell Division; Deferoxamine; DNA; Drug Hypersensitivity; Hearing Disorders; Humans; Pulmon | 1989 |
23 other studies available for deferoxamine and Day Blindness
| Article | Year |
|---|---|
Multimodal imaging in a case of deferoxamine-induced maculopathy.
Topics: beta-Thalassemia; Deferoxamine; Humans; Iron Chelating Agents; Male; Middle Aged; Retinal Diseases; | 2014 |
Bilateral central serous retinopathy in a patient with paroxysmal nocturnal hemoglobinuria treated with deferoxamine.
Topics: Central Serous Chorioretinopathy; Deferoxamine; Fluorescein Angiography; Fundus Oculi; Hemoglobinuri | 2016 |
Deferoxamine-related ocular toxicity: incidence and outcome in a pediatric population.
Topics: Child; Deferoxamine; Female; Hemochromatosis; Humans; Incidence; Iron Chelating Agents; Male; Monito | 2008 |
Desferrioxamine related maculopathy: a case report.
Topics: Aged; Aged, 80 and over; Atrophy; Deferoxamine; Diagnosis, Differential; Female; Glaucoma, Open-Angl | 2004 |
Auditory and visual toxicity during deferoxamine therapy in transfusion-dependent patients.
Topics: Acoustic Impedance Tests; Adolescent; Adult; Anemia, Hemolytic, Congenital; beta-Thalassemia; Chelat | 2005 |
Desferrioxamine, ocular toxicity, and trace metals.
Topics: Deferoxamine; Humans; Renal Dialysis; Trace Elements; Vision Disorders | 1983 |
Visual loss in patient on high-dose subcutaneous desferrioxamine.
Topics: Child; Deferoxamine; Female; Humans; Injections, Subcutaneous; Thalassemia; Vision Disorders | 1984 |
[Ocular findings in Desferal therapy].
Topics: Adolescent; Adult; beta-Thalassemia; Child; Child, Preschool; Deferoxamine; Dose-Response Relationsh | 1995 |
Prevention of postasphyxia electroretinal dysfunction with a pyridoxal hydrazone.
Topics: Animals; Animals, Newborn; Asphyxia Neonatorum; Deferoxamine; Disease Models, Animal; Electroretinog | 1997 |
Contrast sensitivity function in patients with beta-thalassemia major.
Topics: Adolescent; Adult; beta-Thalassemia; Blood Transfusion; Chelation Therapy; Contrast Sensitivity; Def | 2000 |
Neurophysiological and neuro-otological study of homozygous beta-thalassemia under long-term desferrioxamine (DFO) treatment.
Topics: Adult; Audiometry, Pure-Tone; Auditory Threshold; Blood Transfusion; Brain Stem; Deferoxamine; Elect | 1991 |
Acute visual disorders in patients on regular dialysis given desferrioxamine as a test.
Topics: Aged; Aluminum; Deferoxamine; Eye; Female; Humans; Male; Middle Aged; Ocular Physiological Phenomena | 1990 |
Ocular and auditory toxicity in hemodialyzed patients receiving desferrioxamine.
Topics: Adult; Aged; Aged, 80 and over; Aluminum; Chelation Therapy; Deferoxamine; Female; Hearing Loss, Bil | 1990 |
Vision and hearing during deferoxamine therapy.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Chelation Therapy; Child; Deferoxamine; Ferritins; Hearing L | 1990 |
Ocular toxicity of desferrioxamine--an example of copper promoted auto-oxidative damage?
Topics: Aged; Copper; Deferoxamine; Electrooculography; Electroretinography; Evoked Potentials, Visual; Eye | 1989 |
Ocular toxicity of desferrioxamine.
Topics: Deferoxamine; Female; Humans; Middle Aged; Vision Disorders | 1985 |
Acute visual and auditory neurotoxicity in patients with end-stage renal disease receiving desferrioxamine.
Topics: Acute Disease; Adult; Aged; Deferoxamine; Female; Hearing Loss; Hearing Loss, Bilateral; Hearing Los | 1988 |
Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions.
Topics: Adolescent; Adult; Age Factors; Anemia, Aplastic; Audiometry; Child; Child, Preschool; Color Vision | 1986 |
Serial studies of auditory neurotoxicity in patients receiving deferoxamine therapy.
Topics: Adolescent; Adult; Audiometry; Child; Child, Preschool; Deferoxamine; Hearing Loss; Hearing Loss, Hi | 1987 |
[Severe ocular toxicity of desferrioxamine in the hemodialyzed patient].
Topics: Aged; Aluminum; Deferoxamine; Humans; Kidney Failure, Chronic; Male; Renal Dialysis; Retinitis Pigme | 1987 |
Ocular toxicity after a single intravenous dose of desferrioxamine in 2 hemodialyzed patients.
Topics: Aged; Color Perception; Deferoxamine; Female; Humans; Renal Dialysis; Vision Disorders | 1987 |
Ocular and auditory toxicity of long-term, high-dose subcutaneous deferoxamine therapy.
Topics: Child, Preschool; Deferoxamine; Ear; Eye; Female; Hearing Loss, Sensorineural; Humans; Injections, S | 1985 |
[Harmful effects of common drugs on the visual apparatus. The oligo-elements and chelating agents. B. Chelating agents].
Topics: Chelating Agents; Deferoxamine; Dimercaprol; Edetic Acid; Eye Diseases; Humans; Penicillamine; Visio | 1972 |